Risk Factors and Hepatocellular Cancer Screening After Hepatitis C Virus Eradication

Hepatocellular cancer (HCC) usually develops against the background of chronic liver disease. Until recently, the most common etiology of HCC was infection with hepatitis C virus (HCV). The appearance of direct-acting antiviral drugs (DAAD) has become a big breakthrough in the treatment of HCV infection. A stable virological response can now be achieved in almost all treated patients, even in people at high risk of HCC, primarily with cirrhosis of the liver. At the same time, reports gradually began to accumulate about the continued risk of malignant transformation after successful therapy of DAAD. Simultaneously with the decrease in the burden of cirrhosis caused by HCV, the etiological role of non-alcoholic fatty liver disease (NAFLD) has sharply increased. Moreover, in a significant part of patients with NAFLD, HCC is formed at the pre-cirrhotic stage. These changes in the etiology and epidemiology of HCC suggest the revision of patient management tactics

Download Full-text

Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct‑acting antiviral treatment: All Kagawa Liver Disease Group Study

Oncology Letters ◽

10.3892/ol.2020.11341 ◽

2020 ◽

Cited By ~ 2

Author(s):

Joji Tani ◽

Asahiro Morishita ◽

Teppei Sakamoto ◽

Kei Takuma ◽

Mai Nakahara ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Scoring System ◽

Antiviral Treatment ◽

Disease Group ◽

Virus Eradication ◽

Direct Acting Antiviral ◽

Direct Acting

Download Full-text

Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection

Viral Hepatitis Journal ◽

10.4274/vhd.galenos.2020.2020.0016 ◽

2020 ◽

Vol 26 (2) ◽

pp. 43-48

Author(s):

Mustafa Doğan ◽

Birol Topçu ◽

Rıtvan Karaali ◽

İlknur Erdem

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Chronic Liver Disease ◽

Antiviral Drugs ◽

Chronic Liver ◽

Treatment Results ◽

Virus Genotype ◽

Direct Acting Antiviral ◽

Direct Acting

Download Full-text

Hepatitis C virus eradication with direct‐acting antiviral improves insulin resistance

Journal of Viral Hepatitis ◽

10.1111/jvh.13215 ◽

2019 ◽

Vol 27 (2) ◽

pp. 188-194 ◽

Cited By ~ 2

Author(s):

Francesco Paolo Russo ◽

Alberto Zanetto ◽

Martina Gambato ◽

Ilaria Bortoluzzi ◽

Ramona Al Zoairy ◽

...

Keyword(s):

Insulin Resistance ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Eradication ◽

Direct Acting Antiviral ◽

Direct Acting

Download Full-text

Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia

Journal of Hepatology ◽

10.1016/j.jhep.2019.04.014 ◽

2019 ◽

Vol 71 (2) ◽

pp. 281-288 ◽

Cited By ~ 17

Author(s):

Maryam Alavi ◽

Matthew G. Law ◽

Heather Valerio ◽

Jason Grebely ◽

Janaki Amin ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Antiviral Therapy ◽

Disease Burden ◽

New South ◽

Direct Acting Antiviral ◽

South Wales ◽

Related Liver Disease ◽

Direct Acting

Download Full-text

Hepatitis C virus testing, liver disease assessment and direct‐acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study

Journal of Viral Hepatitis ◽

10.1111/jvh.13112 ◽

2019 ◽

Cited By ~ 3

Author(s):

Sahar Bajis ◽

Jason Grebely ◽

Lucy Cooper ◽

Julie Smith ◽

Greg Owen ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Antiviral Treatment ◽

Disease Assessment ◽

Direct Acting Antiviral ◽

Treatment Uptake ◽

Direct Acting ◽

Virus Testing ◽

Sydney Australia

Download Full-text

Post-treatment Mac-2-Binding Protein is a Useful Predictor of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication

10.21203/rs.3.rs-276843/v1 ◽

2021 ◽

Author(s):

Shunsuke Sato ◽

Hironori Tsuzura ◽

Yuji Kita ◽

Yuji Ikeda ◽

Daishi Kabemura ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Liver Fibrosis ◽

Binding Protein ◽

Virologic Response ◽

Virus Eradication ◽

Direct Acting Antiviral ◽

Noninvasive Biomarker ◽

Direct Acting

Abstract Background and aims: Recent advances of direct-acting antiviral drugs for hepatitis C virus (HCV) have dramatically improved the sustained virologic response (SVR) rate, but hepatocellular carcinoma (HCC) development not rarely occurs even in patients who achieve an SVR. Wisteria ﬂoribunda agglutinin-positive Mac-2-binding protein (WFA+-M2BP) was recently developed as a noninvasive biomarker of liver fibrosis. However, the association between the WFA+-M2BP level and HCC development after the achievement of an SVR is unclear. Methods: We examined the association between WFA+-M2BP and HCC development in 552 HCV patients who achieved an SVR (Interferon [IFN]-based therapy, n=228; IFN-free therapy, n=294). Results: Multivariate analysis revealed that a high WFA+-M2BP level at SVR week 24 after treatment (SVR24) (hazard ratio [HR]=1.215, P=0.020), low platelet counts (HR=0.876, P=0.037) and old age (HR=1.073, P=0.012) were independent risk factors for HCC development regardless of the treatment regimen. Receiver operator characteristics curve analysis revealed that an WFA+-M2BP level at SVR24 of ≥1.62 cut off index (COI) was the cut-off value for the prediction of HCC development (adjusted HR = 12.565, 95% CI 3.501-45.092, P<0.001). The 3- and 5-year cumulative incidences of HCC were 0.7% and 0.7% in patients with low WFA+-M2BP at SVR24 (<1.62 COI), and 4.8% and 12.4% in patients with high WFA+-M2BP (≥1.62 COI) were, respectively (P<0.001).Conclusion: The assessment of liver fibrosis using the WFA+-M2BP level at SVR24 is a useful predictor of HCC development after HCV eradication even in the IFN-free therapy era.

Download Full-text